CHARLES FILLINGANE: Open Payments
NPI 1275854465 · MARYVILLE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,236 in 71 payments from 16 companies in 2025. Trend: 2023 $77 · 2024 $1,292 · 2025 $1,236
Food & beverage: $1,221Education: $15
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $379 |
| Otsuka America Pharmaceutical, Inc. | 13 | $201 |
| AstraZeneca Pharmaceuticals LP | 5 | $154 |
| PFIZER INC. | 4 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $78 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| Lundbeck LLC | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Ardelyx, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
Products named: REXULTI, VRAYLAR, QULIPTA, FARXIGA, UBRELVY, PREVNAR 20, CAPLYTA, ZORYVE.
Industry payments across MO — which companies pay providers there.
